Hillstream BioPharma up on cancer research tie-up with Sapien

Canton Strategic Holdings

27/06/2022 14:58

** Shares of biotechnology co Hillstream BioPharma  HILS.O 
jump 29.6% to 97 cents
    ** HILS collaborates with Sapien Biosciences for cancer
treatment research (https://refini.tv/39ZoRCg)
    ** Co is starting studies along with Sapien to test the
synergy of its lead candidate, HSB-1216, with certain approved
cancer drugs including Bristol Myers'  BMY.N  Opdivo
    ** Stock down ~72 since January IPO

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))